Axsome Therapeutics Inc — Quarterly Cash Flow (NASDAQ:AXSM) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 561.46 M568.5 M596.67 M639.78 M669.25 M689.8 M Total liabilities 468.56 M511.48 M543.47 M566.71 M595.52 M601.51 M Total equity 92.9 M57.02 M53.2 M73.08 M73.73 M88.3 M Total liabilities & shareholders' equities 561.46 M568.5 M596.67 M639.78 M669.25 M689.8 M Total debt —————— Net debt ——————

Nachrichten

Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Axsome Therapeutics: UBS hebt Kursziel wegen Vertriebsexpansion an

UBS raises Axsome Therapeutics stock price target on sales force expansion

Wolfe Research nimmt Bewertung für Axsome mit "Outperform" auf/n

Wolfe Research initiates Axsome stock with outperform rating

RBC Capital erhöht Kursziel für Axsome Therapeutics nach Quartalszahlen

RBC Capital raises Axsome Therapeutics price target on earnings

Axsome startet Phase-3-Studie mit Solriamfetol zur Behandlung von Depressionen

Axsome doses first patient in depression trial with solriamfetol

Guggenheim hebt Kursziel für Axsome wegen starker Absatzzahlen auf 220 US-Dollar an